Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

PHASE3CompletedINTERVENTIONAL
Enrollment

1,002

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

January 31, 2009

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

Indacaterol 150 μg

Indacaterol 150 μg once daily (o.d) inhaled

DRUG

Salmeterol 50 μg

Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler

DRUG

Placebo to Indacaterol

Placebo to Indacaterol inhaled via SDDPI.

DRUG

Placebo to Salmeterol

Placebo to salmeterol delivered via a proprietary dry powder inhaler

Trial Locations (128)

Unknown

Novartis Investigative Site, Edmonton

Novartis Investigator Site, Edmonton

Novartis Investigator Site, London

Novartis Investigator Site, Mirabel

Novartis Investigator Site, Montreal

Novartis Investigator Site, Toronto

Novartis Investigator site, Barranquilla

Novartis Investigator Site, Bogota D.C.

Novartis Investigator Site, Medellín

Novartis Investigator Site, Cvikov

Novartis Investigator Site, Lovosice

novartis Investigator site, Novy Jocin

Novartis Investigator Site, Pardubice

Novartis Investigator Site, Prague

Novartis Investigative Site, Žatec

Novartis Investigator Site, Aalborg

Novartis Investigator Site, Aarhus

Novartis Investigative Site, Copenhagen

Novartis Investigator Site, Copenhagen

Novartis Investigator Site, Frederikssund

Novartis investigator site, Hellerup

Novartis Investigator site, Hvidovre

Novartis investigator site, Odense

Novartis Investigator Site, Roslev

Novartis Investigative Site, Silkeborg

Novartis Investgative Site, Søborg

Novartis Investigator Site, Vaerloese

Novartis Investigator Site, Hus

Novartis Investigator Site, Jyväskylä

Novartis Investigator Site, Lahti

Novartis Investigator Site, Oulu

Novartis Investigator Site, Tampere

Novartis Investigator Site, Turku

Novartis Investigative Site, Ambroise

Novartis Investigative Site, Beuvry

Novartis Investgative Site, Férolles-Attilly

Novartis Investigator Site, Nice

Novartis Investigator Site, Bad Segeberg

Novartis Investigator Site, Berlin

Novartis Investigator Site, Bielefeld

Novartis Investigator Site, Bochum

Novartis Investigator Site, Bonn

Novartis Investigator Site, Brühl

Novartis Investigator Site, Cologne

Novartis Investigator Site, Cottbus

Novartis Investigator Site, Dortmund

Novartis Investigator Site, Düren

Novartis Investigator Site, Eggenfelden

Novartis investigator site, Eschwege

Novartis Investigator Site, Forchheim

Novartis Investigator Site, Freudenberg

Novartis Investigator Site, Fürth

Novartis Investigator Site, Gelsenkirchen

Novartis Investigator Site, Gummersbach

Novartis Investigator Site, Hagen

Novartis Investigator Site, Hanover

Novartis Investigator Site, Kassel

Novartis Investigator Site, Kempten

Novartis Investigator Site, Landsberg am Lech

Novartis Investigator Site, Langenfeld

Novartis Investigator Site, Leipzig

Novartis Investigator Site, Mainz

Novartis Investigator Site, Munich

Novartis Investigator Site, München

Novartis Investigator Site, Neuss

Novartis Investigator Site, Nuremberg

Novartis Investigator Site, Oschersleben

Novartis Investigator Site, Ruhmannsfelden

Novartis Investigator site, Sinsheim

Novartis Investigator Site, Solingen

Novartis Investigator Site, Steinfort-borghorst

Novartis Investigator Site, Vilshofen

Novartis Investigator Site, Wallerfing

Novartis Investigator Site, Witten

Novartis Investigator Site, Budapest

Novartis investigator site, Debrechen

Novartis Investigator Site, Deszk

Novartis Investigator Site, Mosonmagyaróvár

Novartis Investigator Site, Székesfehérvár

Novartis investigator site, Reykhavik

Novartis Investigator Site, Chennai

Novartis Investigator Site, Coimbatore

Novartis Investigator Site, Goa

Novartis Investigator Site, Hyderabad

Novartis Investigator Site, Jaipur

Novartis Investigator Site, Kerala

Novartis Investigator Site, Mangalore

Novartis Investigator Site, Mumbai

Novartis Investigator Site, Vellore

Novartis Investigator Site, Ancona

Novartis Investigator Site, Arenzano

Novartis Investigative Site, Ascoli Piceno

Novartis Investigator Site, Brescia

Novartis Investigator Site, Cagliari

Novartis investigator site, Chieti

Novartis Investigator Site, Ferrara

Novartis Investigator Site, Milan

Novartis Investigator Site, Milan

Novartis Investigator Site, Orbassano

Novartis Investigator Site, Palermo

Novartis Investigator Site, Reggio Emilia

Novartis Investigator Site, Rome

Novartis Investigator Site, Sexten

Novartis Investigator Site, Siena

Novartis Investigator Site, Terni

Novartis Investigator Site, Callao

Novartis Investigator Site, Miraflores

Novartis Investigator Site, San Borja

Novartis Investigator Site, San Isidro

Novartis Investigator Site, San Martín de Porres

Novartis Investigator Site, Surco

Novartis Investigator Site, Kazan'

Novartis Investigator Site, Moscow

Novartis Investigator Site, Saint Petersburg

Novartis Investigator Site, Samara

Novartis Investigator Site, Yaroslavl

Novartis Investigator Site, Yekaterinburg

Novartis Investigator Site, Bardejov

Novartis Investigator Site, Bratislava

Novartis Investigator Site, Košice

Novartis Investigator Site, Kovice

Novartis Investigator Site, Spišská Nová Ves

Novartis Investigator Site, Changhua

Novartis Investigator Site, Kaohsiung City

Novartis Investigator Site, Kaohusing

Novartis Investigator Site, Lin-ko

Novartis Investigator Site, Taichung

Novartis Investigator Site, Taipei

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00567996 - Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control | Biotech Hunter | Biotech Hunter